SHANGHAI, China, July 24 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (“WuXi PharmaTech” or “the Company”), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the second quarter 2008 after the US market close on Wednesday, August 13, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
The earnings release will be available on the investor relations section of its website at http://www.wuxipharmatech.com.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Thursday, August 14, 2008 to discuss its 2008 second quarter financial results and recent business activities. The conference call may be accessed by calling:
A telephone replay will be available shortly after the call until September 14, 2008 at (US) 888-203-1112/ (HK) 800-901-108 / (China, Southern Region) 10-800-140-1178 / (China, Northern Region) +1-719-457-0820 / (UK) +0808-101-1153. Passcode: 2740550.
A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech’s website at http://www.wuxipharmatech.com .
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .
CONTACT: Dr. Hai Mi, Vice President, Corporate Communications, WuXi
PharmaTech Co., Ltd. at +86-21-5046-3726 or ir@pharmatechs.com; Investor
Relations (US): Mahmoud Siddig, Director, Taylor Rafferty at
+1-212-889-4350 or Pharmatechs@taylor-rafferty.com; Investor Relations
(HK): Ruby Yim, Managing Director, Taylor Rafferty at +852-3196-3712 or
Pharmatechs@taylor- rafferty.com; Media Contact: John Dudzinsky, Director,
Taylor Rafferty at +1- 212-889-4350 or Pharmatechs@taylor-rafferty.com, all
for WuXi PharmaTech Co., Ltd.
Web site: http://www.wuxipharmatech.com/
